Skip to main content
All lobbying filings

LUNDBECK LLC

Lobbying for LUNDBECK LLC

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 16, 2026
Expenses
$130,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to Pharmacy Benefit Managers - H.R.4317, PBM Reform Act of 2025; H.R.6703, Lower Health Care Premiums for All Americans Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Reauthorization of the Pediatric Priority Review Voucher program at the FDA Issues related to DTC advertising regulations Pediatric rare diseases - H.R. 1262 & S. 932, Give Kids a Chance Act of 2025 Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act

Issues pertaining to the 340B Drug Discount Program - H.R. 5256, 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to Pharmacy Benefit Managers - S.3345, PBM Price Transparency and Accountability Act; H.R.4317, PBM Reform Act of 2025 Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations

Tariffs on pharmaceutical products

 Bills named in this filing 19
  • H.R. 5256
    340B ACCESS Act
  • H.R. 4581
    340B PATIENTS Act of 2025
  • S. 2372
    340B PATIENTS Act of 2025
  • H.R. 4317
    PBM Reform Act of 2025
  • H.R. 6703
    Lower Health Care Premiums for All Americans Act
  • H.R. 5509
    Safe Step Act
  • S. 2903
    Safe Step Act
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • S. 932
    Give Kids a Chance Act of 2025
  • H.R. 5536
    HEADACHE Act
  • H.R. 1189
    National Plan for Epilepsy Act
  • S. 494
    National Plan for Epilepsy Act
  • H.R. 6166
    Lowering Drug Costs for American Families Act
  • S. 3345
    PBM Price Transparency and Accountability Act
  • H.R. 946
    ORPHAN Cures Act
  • S. 1862
    ORPHAN Cures Act
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S. 832
    EPIC Act of 2025
  • H.R. 7837
    Most Favored Patient Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem